Abstract 5-Aminosalicylic acid (5-ASA) has structural similarities to both phenacetin and aspirin, which are known to cause 'analgesic nephropathy'. Because of the increasing use of 5-ASA, this paper draws attention to two cases of severe interstitial nephritis resulting from 5-ASA and emphasises the importance of monitoring renal functions of patients with inflammatory bowel disease who are receiving 5-ASA preparations. (Gut 1994; 35: 1493-1496 45 ml/minute and urine protein was 2-9 g/24 hours. Asacol was stopped. Renal ultrasound, urine microscopy, calcium anti-glomerular basement membrane antibodies (GBM), antinuclear antibodies (ANA), rheumatoid factor, DNA binding, anti-cardiolipin antibody, cryoglobulins, immunoglobulins, and complements were either normal or negative. His creatinine clearance remained at 49 ml/min at three months after treatment with the drug had finished and a renal biopsy performed at that stage showed severe interstitial nephritis (Figure) . A trial of prednisolone 60 mg daily was given without any improvement in renal functions. At the time of reporting he had developed hypertension, which required medical treatment. The ulcerative colitis has remained quiescent without any treatment.
and creatinine (394 mmol/1) values. Creatinine clearance was 45 ml/minute and urine protein was 2-9 g/24 hours. Asacol was stopped. Renal ultrasound, urine microscopy, calcium anti-glomerular basement membrane antibodies (GBM), antinuclear antibodies (ANA), rheumatoid factor, DNA binding, anti-cardiolipin antibody, cryoglobulins, immunoglobulins, and complements were either normal or negative. His creatinine clearance remained at 49 ml/min at three months after treatment with the drug had finished and a renal biopsy performed at that stage showed severe interstitial nephritis (Figure) . A trial of prednisolone 60 mg daily was given without any improvement in renal functions. At the time of reporting he had developed hypertension, which required medical treatment. The ulcerative colitis has remained quiescent without any treatment. Despite the theoretical risk of microcrystallisation of sulfapyridine in the renal tubules, only few cases of renal toxicity have been reported with sulphasalazine use.11 12 In the small number of published reports, renal toxicity was seen as a part of a generalised hypersensitivity reaction to the drug. Since the introduction of 5-ASA, however, five cases of renal toxicity have been published. 13-17 In addition to that, the Committee on Safety of Medicines in England and Wales has released information on nine possible cases of serious nephrotoxicity (four cases of interstitial nephritis, two nephrotic syndrome, and two renal failure) between February 1988 and December 1990 (including the cases reported here).18 Two of these patients had previous allergic reaction to sulphasalazine and one had renal dysfunction while receiving the drug. The two cases reported here were not receiving sulphasalzine before treatment with mesalazine. The significant delay between the onset of renal damage after treatment with mesalazine had started and the absence of other organ dysfunction suggest that the renal toxicity was not caused by a hypersensitivity reaction.
A number of studies have shown a significant correlation between the duration, the intensity, and the total dose of analgesics consumed and the degree of renal impairment.2 3 4 8 Our patients were receiving mesalazine 800 mg three times daily for 18-24 months when they were found to have renal impairment. 5-ASA is acetylated, independent of the acetylator status, to N-acetyl 5-ASA in the wall of ileum and colon.'9 5-ASA is absorbed in both the acetylated and nonacetylated form and once absorbed behaves similarily to other salicylates. Although it has been suggested that non-acetylated salicylates are less nephrotoxic,20 21 more recent studies have shown that both acetylated and nonacetylated forms of salicylate induce renal damage at similar doses.4-7 22 Under normal physiological conditions over 80% salicylate is inactivated in hepatic mitochondria to salicylurate, which is not known to cause uncoupling of oxidative phosphorylation in renal mitochondria. In the kidney salicylate is filtered and secreted by proximal tubules. Passive reabsorption occurs throughout the nephron resulting in high cortical and medullary concentration compared with the plasma concentrations.8 Clearance of salicylate, possibly related to saturation of the secretory mechanism, shows a direct correlation with urine flow and negative correlation with the plasma concentration.
The absorption of 5-ASA and acetyl-5-ASA is predominantly from the small intestine.23 24 Plasma concentrations of 5-ASA and acetyl-5-ASA are higher in subjects with intact colon compared with those with ileostomy.25
The considerable individual variation in the absorption of these compounds makes it difficult to compare the published data on small group of subjects,26 yet detection of these compounds in subjects who had only enema preparations of 5-ASA or acetyl-5-ASA suggest that significant absorption may take place in the colon.27 The absorption from small bowel and colon depend on the pH, the transit time, the mode of delivery of the drug, and perhaps the integrity of the mucosa. [25] [26] [27] [28] [29] [30] [31] Of these, the mode of delivery may be an important factor determining the peak plasma concentrations and thereby renal toxicity. On the basis of serum and 24 hour urinary excretion of 5-ASA and acetyl-5-ASA, it seems that maximum absorption is from plain 5-ASA preparations (almost 100%) followed by Asacol (20-30%), Pentasa (28-36%), and Dipentum (22-25%) in that order. The absorption from Asacol (coated with Eudragit S) seems to be lower than similar compounds like Claversal and Salofalk (coated with Eudragit L); this is related to the more proximal release of 5-ASA from these preparations.25 31 It is interesting to note that the serum concentrations of 5-ASA and acetyl-5-ASA from Pentasa, designed to deliver 5-ASA throughout the small bowel, is less than Asacol and similar compounds. This may result from incomplete release of 5-ASA from the granules26; or perhaps because the slow delivery does not overwhelm the acetylation capacity of the intestinal mucosa32 and assuming that acetyl-5-ASA is less well absorbed than 5-ASA. The absorption from olsalazine (Dipentum) seems to be similar to sulphasalazine making this compound, at least theoretically, less nephrotoxic.3' Our patients had total colitis. It is difficult to know whether this has predisposed them to the toxic effects of Asacol. It is possible that backwash ileitis and the change in pH may have led to the release of 5-ASA more proximally in the small bowel. Inflammation may also modify the mucosal acetylation and the absorption of 5-ASA and acetyl-5-ASA. The available data are insufficient, however, to find out if the absorption and the acetylation of 5-ASA compounds are related either to the extent or the severity of the disease.
Renal damage resulting from smaller doses of Asacol (400 mg three times daily) has also been reported suggesting that factors other than the amount of drug ingested may be involved. It has been suggested that prostaglandin inhibition enhances renal damage in the presence of hypovolaemia and salt depletion.4 With reference to this report, intravascular volume depletion resulting from diarrhoea may be a predisposing factor in patients with active inflammatory bowel disease. The longterm prognosis of our patients remain unclear. There has been no deterioration in renal functions since the drug was withdrawn, but the follow up of these patients has not been long enough to predict the future course. In patients with analgesic nephropathy, about a third improve, a third remain stable, and a third deteriorate. 33 In the case of analgesics, NSAIDs and 5-ASA, only a few patients develop renal damage. Patients with inflammatory bowel disease are more susceptible to damage because they will probably become dehydrated during exacerbation of their disease. As Asacol has been on the market longer than some other 5-ASA preparations, it is possible that nephrotoxicity may be noted with other preparations in the future. Sterile pyuria and low specific gravity are early features in salicylate induced renal damage. Proteinuria and hypertension may suggest advanced disease. As there are definite advantages in using 5-ASA preparations over sulphasalazine in the treatment of inflammatory bowel disease, especially the higher doses in small bowel Crohn's disease, it will be important to monitor renal functions and urine microscopy.
